NewAmsterdam Pharma Unveils Promising Phase 3 Trial Results

NewAmsterdam Pharma Company ( (NAMS) ) has issued an announcement.

NewAmsterdam Pharma has announced promising results from its Phase 3 BROADWAY trial, revealing that obicetrapib significantly reduces LDL cholesterol levels and major adverse cardiovascular events in patients with cardiovascular disease. The trial demonstrated a 33% reduction in LDL-C and a 21% reduction in cardiovascular events, with obicetrapib being well-tolerated, comparing favorably to placebo. These findings suggest obicetrapib could offer a new, effective oral treatment for those struggling to manage cholesterol levels despite existing therapies.

Find detailed analytics on NAMS stock on TipRanks’ Stock Analysis page.